| scholarly article | Q13442814 |
| P50 | author | Bouke P Hazenberg | Q57219791 |
| P2093 | author name string | B A C Dijkmans | |
| I E van der Horst-Bruinsma | |||
| I C van Eijk | |||
| M J L Peters | |||
| M T Nurmohamed | |||
| R J van de Stadt | |||
| J H M Levels | |||
| G J Wolbink | |||
| M K de Vries | |||
| E E Huizer | |||
| P2860 | cites work | Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria | Q34055060 |
| Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk | Q40217679 | ||
| Influence of serum amyloid A on cholesterol esterification in human plasma | Q43486904 | ||
| P433 | issue | 5 | |
| P921 | main subject | lipoprotein | Q28350 |
| P304 | page(s) | 1324-1330 | |
| P577 | publication date | 2009-05-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis | |
| P478 | volume | 60 |
| Q37618334 | A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis |
| Q97421408 | An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision |
| Q85069915 | Biologics and cardiovascular risk |
| Q38025994 | Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights |
| Q33709082 | Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis |
| Q38115132 | Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm |
| Q38741861 | Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism |
| Q57605596 | DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen |
| Q35352554 | Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study |
| Q38177340 | Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk |
| Q36245981 | High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study |
| Q48003836 | Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis |
| Q38722298 | Inflammatory cytokines in atherosclerosis: current therapeutic approaches. |
| Q46195508 | Lipid profile and anti-TNF-α use. |
| Q38181566 | Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: a meta-analysis of prospective studies |
| Q35112757 | Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment. |
| Q90142748 | Nonsteroidal Anti-inflammatory Drug use is Associated with Incident Hypertension in Ankylosing Spondylitis |
| Q51045110 | Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment. |
| Q48244028 | Prevalence of metabolic syndrome in children with moderate to severe psoriasis treated with TNF inhibitors in comparison to conventional agents. |
| Q40324538 | Radiographic progression is associated with increased cardiovascular risk in patients with axial spondyloarthritis |
| Q40065441 | Sex and Cardiovascular Involvement in Inflammatory Joint Diseases |
| Q35257568 | Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis |
| Q34613907 | Spondyloarthritides: evolving therapies |
| Q37801353 | Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis |
| Q37689488 | Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins |
| Q38519523 | Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. |
| Q50109832 | The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review |
| Q37625670 | Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies |
| Q92121586 | Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study |
| Q37630351 | Vascular effects of biologic agents in RA and spondyloarthropathies |
| Q84514358 | [Development of morbidity and mortality in patients with spondyloarthritis] |
Search more.